• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cytomegalovirus infection after autologous transplantation in patients with multiple myeloma exposed to daratumumab.

作者信息

Liberatore Carmine, D'Uva Mario, Natale Annalisa, Guardalupi Francesco, Di Re Lucia, Fioritoni Francesca, Pulini Stefano, Spadano Raffaele, Vaddinelli Doriana, Santarone Stella, Di Ianni Mauro

机构信息

Department of Medicine and Aging Sciences, "G d'Annunzio" University, Chieti, Italy.

Hematology Unit, Santo Spirito Hospital, Pescara, Italy.

出版信息

Bone Marrow Transplant. 2025 May 13. doi: 10.1038/s41409-025-02624-z.

DOI:10.1038/s41409-025-02624-z
PMID:40360761
Abstract
摘要

相似文献

1
Cytomegalovirus infection after autologous transplantation in patients with multiple myeloma exposed to daratumumab.接受达雷妥尤单抗治疗的多发性骨髓瘤患者自体移植后的巨细胞病毒感染
Bone Marrow Transplant. 2025 May 13. doi: 10.1038/s41409-025-02624-z.
2
Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis.达雷妥尤单抗联合标准治疗方案用于初诊多发性骨髓瘤患者：一项网状 Meta 分析。
Eur J Haematol. 2019 Dec;103(6):542-551. doi: 10.1111/ejh.13317. Epub 2019 Oct 1.
3
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.复发或难治性多发性骨髓瘤患者中，贝兰他单抗马福多汀、硼替佐米与地塞米松联合用药对比达雷妥尤单抗、硼替佐米与地塞米松联合用药的患者报告结局（DREAMM-7）：一项3期、开放标签、随机对照试验的结果
Lancet Haematol. 2025 Jul 15. doi: 10.1016/S2352-3026(25)00163-2.
4
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
5
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
6
[Effect of Daratumumab, Lenalidomide, and Dexamethasone on Quality of Life in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Stem Cell Transplantation].达雷妥尤单抗、来那度胺和地塞米松对新诊断的不适合进行干细胞移植的多发性骨髓瘤患者生活质量的影响
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Jun;33(3):816-821. doi: 10.19746/j.cnki.issn.1009-2137.2025.03.028.
7
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.CD200免疫检查点表达与接受抗CD38单克隆抗体治疗的多发性骨髓瘤患者的较差预后相关。
Oncoimmunology. 2025 Dec;14(1):2532226. doi: 10.1080/2162402X.2025.2532226. Epub 2025 Jul 20.
8
Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma.在新诊断多发性骨髓瘤患者接受达雷妥尤单抗治疗期间发生巨细胞病毒感染。
Int J Hematol. 2024 Jul;120(1):91-95. doi: 10.1007/s12185-024-03770-8. Epub 2024 Apr 19.
9
Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization.优化多发性骨髓瘤的自体干细胞移植：强化化疗动员的影响
Transplant Cell Ther. 2024 Aug;30(8):774.e1-774.e12. doi: 10.1016/j.jtct.2024.05.016. Epub 2024 May 18.
10
Real-World Effectiveness and Safety of Intravenous Daratumumab in Patients with Multiple Myeloma: A Multicenter, Observational Study from Korea.静脉注射达雷妥尤单抗治疗多发性骨髓瘤患者的真实世界有效性和安全性：一项来自韩国的多中心观察性研究。
Cancer Res Treat. 2025 Jul;57(3):883-890. doi: 10.4143/crt.2024.781. Epub 2024 Dec 24.

本文引用的文献

1
Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis.接受基于抗CD38单克隆抗体方案治疗的多发性骨髓瘤患者感染的累积发病率和相对风险：一项系统评价和荟萃分析。
Open Forum Infect Dis. 2022 Oct 31;9(11):ofac574. doi: 10.1093/ofid/ofac574. eCollection 2022 Nov.
2
Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies.同种异体造血干细胞移植和实体器官移植中巨细胞病毒感染的评估和预防：意大利 GITMO、SITO 和 AMCLI 学会的多学科共识会议。
Clin Transplant. 2019 Oct;33(10):e13666. doi: 10.1111/ctr.13666. Epub 2019 Aug 6.
3
Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma.达雷妥尤单抗治疗多发性骨髓瘤后的感染性并发症和 NK 细胞耗竭。
PLoS One. 2019 Feb 13;14(2):e0211927. doi: 10.1371/journal.pone.0211927. eCollection 2019.
4
Infectious and immunological sequelae of daratumumab in multiple myeloma.达雷妥尤单抗在多发性骨髓瘤中的感染性和免疫性后遗症
Br J Haematol. 2019 Apr;185(1):187-189. doi: 10.1111/bjh.15433. Epub 2018 Jul 5.
5
Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.淋巴瘤和骨髓瘤患者接受自体外周血造血干细胞移植后巨细胞病毒再激活。
J Clin Virol. 2017 Oct;95:36-41. doi: 10.1016/j.jcv.2017.08.006. Epub 2017 Aug 18.
6
Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant.除同种异体移植外的血液系统恶性肿瘤环境中的巨细胞病毒感染
Hematol Oncol. 2018 Apr;36(2):381-391. doi: 10.1002/hon.2453. Epub 2017 Jun 29.
7
Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.用于临床试验的移植患者巨细胞病毒感染和疾病的定义。
Clin Infect Dis. 2017 Jan 1;64(1):87-91. doi: 10.1093/cid/ciw668. Epub 2016 Sep 28.
8
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.达雷妥尤单抗可清除CD38+免疫调节细胞，促进T细胞扩增，并使多发性骨髓瘤中的T细胞库发生偏移。
Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.
9
Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.接受串联自体干细胞移植和新型药物治疗的骨髓瘤患者出现症状性巨细胞病毒再激活风险的评估：一项单机构研究。
Transpl Infect Dis. 2014 Dec;16(6):1032-8. doi: 10.1111/tid.12309. Epub 2014 Nov 5.
10
High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.接受基于硼替佐米方案治疗后进行自体干细胞移植的骨髓瘤患者移植后巨细胞病毒再激活的高发生率：来自罗马移植网络的一项调查
Transpl Infect Dis. 2014 Feb;16(1):158-64. doi: 10.1111/tid.12162. Epub 2013 Nov 12.